Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv net income
Net income is the profit left for shareholders after every expense, interest and tax.
Pharma-Bio Serv's net income for the twelve months ending Jul 31, 2026 was $251.53K. For fiscal 2025 it was -$100.46K. The highest annual figure on record is $4.91M in fiscal 2013.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$100.46K | – |
| FY2024 | Oct 31, 2024 | -$777.62K | -159.4% |
| FY2023 | Oct 31, 2023 | $1.31M | +30.1% |
| FY2022 | Oct 31, 2022 | $1.01M | – |
| FY2021 | Oct 31, 2021 | -$2.09M | -201.9% |
| FY2020 | Oct 31, 2020 | $2.05M | -1.7% |
| FY2019 | Oct 31, 2019 | $2.09M | +63.1% |
| FY2018 | Oct 31, 2018 | $1.28M | – |
| FY2017 | Oct 31, 2017 | -$1.41M | – |
| FY2016 | Oct 31, 2016 | -$256.58K | -115.8% |
| FY2015 | Oct 31, 2015 | $1.62M | -32.7% |
| FY2014 | Oct 31, 2014 | $2.41M | -50.8% |
| FY2013 | Oct 31, 2013 | $4.91M | +4.7% |
| FY2012 | Oct 31, 2012 | $4.69M | +48.4% |
| FY2011 | Oct 31, 2011 | $3.16M | +749.4% |
| FY2010 | Oct 31, 2010 | $371.91K | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$14.22K | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $232.99K | +144.3% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $32.86K | +285.0% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$102 | -100.6% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$204.25K | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $95.35K | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $8.54K | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $16.11K | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$309.19K | -158.8% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$213.82K | -152.8% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$270.72K | -163.5% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$47.15K | -105.7% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $526.24K | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $404.65K | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $426.43K | -81.3% |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | $833.31K | +246.8% |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -$288.03K | -207.5% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -$4.87M | -3475.7% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $2.28M | +228.7% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | $240.27K | -65.1% |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $268.03K | -49.1% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $144.35K | -69.8% |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $692.11K | +60.5% |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | $687.56K | -2.8% |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $526.90K | +11.9% |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | $477.60K | -85.7% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | $431.16K | -41.0% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | $707.48K | – |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | $471.02K | – |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $3.34M | – |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $730.63K | – |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -$128.35K | – |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -$2.66M | – |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -$547.03K | – |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -$162.98K | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -$322.76K | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -$382.14K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -$513.32K | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -$130.47K | – |
See a number that looks wrong?